Skip Navigation

This Article
Right arrow FREE Full Text (PDF) Freely available
Right arrow E-letters: Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when E-letters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Disclaimer
Google Scholar
Right arrow Articles by Sieber, M.
Right arrow Articles by Diehl, V.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Sieber, M.
Right arrow Articles by Diehl, V.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Annals of Oncology 11:S81-S85, 2000
© 2000 European Society for Medical Oncology

Symposium Articles

Treatment of Hodgkin's disease: Results and current concepts of the German Hodgkin's Lymphoma Study Group

M. Sieber, A. Engert and V. Diehl

Klinik I für Innere Medizin Köln, Germany

Correspondence to: V. Diehl, MD Klinik I für Innere Medizin Joseph-Stelzmann-Straße 9 D-50924 Köln Germany E-mail: v.diehl{at}uni-koel.de

Background: Treatment strategies in Hodgkin's disease (HD) are changing fundamentally over the last decades. Both radiotherapy and combination chemotherapy are effective treatment modalities. However, the optimal choice of treatment or combinations of treatment is still debated for different prognostic groups.

Patients and methods: The German Hodgkin's Lymphoma Study Group (GHSG) initiated randomized clinical trials since 1978. Over the past 20 years, more than 6000 patients with HD in all stages were randomized, treated and followed by the GHSG. Patients are now being recruited from more than 300 clinical centers.

Results: As a consequence of different clinical trials, it is now the policy of the GHSG to tailor treatment to the individual risk of patients, giving favorable patients less intensive and less toxic therapy than unfavorable patients. The treatment for early and intermediate stage HD becomes quite similar with few cycles of polychemotherapy followed by involved field irradiation. In advanced stage HD, the introduction of dose intensified chemotherapy (BEACOPP), has improved treatment results and thus will substitute the MOPP or ABVD regimens.

Conclusions: Although most of the patients with HD will be cured by modern treatment stategies, several questions are still subjects of ongoing clinical trials: 1) which chemotherapy regimen in which quantity will be the best with respect to efficacy and toxicity and 2) which dose and field size of radiotherapy is adequate within the combined modality.

ABVD, BEACOPP, chemotherapy, clinical trials, COPP, dose intensification, Hodgkin's disease, radiotherapy, risk factors


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 ASH Education BookHome page
M. E. Juweid
Utility of Positron Emission Tomography (PET) Scanning in Managing Patients with Hodgkin Lymphoma
Hematology, January 1, 2006; 2006(1): 259 - 265.
[Abstract] [Full Text] [PDF]

Home page
 JCOHome page
E. Duhmke, J. Franklin, M. Pfreundschuh, S. Sehlen, N. Willich, U. Ruhl, R.-P. Muller, P. Lukas, A. Atzinger, U. Paulus, et al.
Low-Dose Radiation Is Sufficient for the Noninvolved Extended-Field Treatment in Favorable Early-Stage Hodgkin's Disease: Long-Term Results of a Randomized Trial of Radiotherapy Alone
J. Clin. Oncol., June 1, 2001; 19(11): 2905 - 2914.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.